Fosaprepitant is a widely administered antiemetic used mainly for moderately to highly emetogenic chemotherapy. Local injection site reactions are the most common type of infusion reaction reported from fosaprepitant. At our institution, two separate patients have experienced systemic hypersensitivity reactions to their infusions of fosaprepitant. We report a review of the literature and the details of these reactions.
SaitoHYoshizawaHYoshimoriKet al.Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Ann Oncol2013; 24: 1067–1073.
4.
TsukaharaKNakamuraKMotohashiRet al.Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinoma. Acta Otolaryngol2014; 134: 1198–1204.
5.
GrunbergSChuaDMaruAet al.Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol – EASE. J Clin Oncol2011; 29: 1495–1501.
6.
Merck & Co., Inc. Emend for injection (package insert), Greenville, NC: Merck, 2008.
7.
LasseterKCGambaleJJinBet al.Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol2007; 47: 834–840.
